Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
STRO-002 + Bevacizumab for Ovarian Cancer
Recruiting1 awardPhase 1
Tampa, Florida
This trial tests the safety and effectiveness of combining STRO-002 and Bevacizumab in patients with advanced ovarian cancer that hasn't responded to standard treatments. STRO-002 targets cancer cells directly, and Bevacizumab stops blood vessel growth to tumors.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service